Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Acute Myeloid Leukemia in Children

Brenda E. S. Gibson  1 , Martin G. Sauer  2 , Persis Amrolia  3
Enric Carreras  1 , Carlo Dufour  2 , Mohamad Mohty  3 , Nicolaus Kröger  4
, editors.
In: The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies [Internet]. 7th edition. Cham (CH): Springer; 2019. Chapter 70.
Affiliations
Free Books & Documents
Review

Acute Myeloid Leukemia in Children

Brenda E. S. Gibson et al.
Free Books & Documents

Excerpt

The outcome for children with acute myeloid leukemia (AML) has serially improved over the past three decades with an overall survival (OS) of 70–75% and event-free survival (EFS) of 60–65% widely reported. Much of this improvement is due to better supportive care, optimization of intensity of treatment including employment of Haematopoietic Stem Cell Transplantation (HSCT) in 1st complete remission (CR1) and better salvage in 2nd complete remission (CR2).

PubMed Disclaimer

References

    1. Abrahamsson J, Forestier E, Heldrup J, et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol. 2011;29:310–5. - PubMed
    1. Bitan M, He W, Zhang MJ, et al. Transplantation for children with acute myeloid leukaemia: a comparison of outcomes with reduced intensity and myeloablative regimens. Blood. 2014;123:1615–20. - PMC - PubMed
    1. Buldini B, Rizzati F, Masetti R, et al. Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol. Br J Haematol. 2017;177:116–26. - PubMed
    1. Copelan EA, Hamilton BK, Avalos B, et al. Better leukaemia-free and overall survival in AML in first remission following cyclophosphamide in combination with Busulfan compared with TBI. Blood. 2013;122:3863–70. - PMC - PubMed
    1. Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European LeukaemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated–risk adapted approach. Nat Rev Clin Oncol. 2012;9:579–90. - PubMed

LinkOut - more resources